Scanfil reported a very good Q1, and the outlook has improved for the remainder of this year.
Redeye retains its positive view of Formpipe following a solid Q1 report with robust ACV and early s...
Slow start to '23, but March better, 4m-5m EE milestones delayed -14% y-o-y EBIT drop caused by temp...
Q1 report due on Friday, 28 April We expect the strong UK trend to continue despite fibre fears.
Redeye returns with a research update following the Q1 report.
Beijer Group reported a strong Q1 2023, which saw sales jump above the SEK600m mark.
Sales +6% y-o-y, -3% vs. ABGSCe 6% EBIT margin (3% in Q1'22), supported by slowdown in opex Cons.
Redeye comments on Scandinavian ChemoTech’s TO3 exercise, which generated SEK7.
Redeye comments on SenzaGen’s Q1 2023 sales update, where sales during the first quarter amounted to...
Redeye comments on Xspray following today’s news that the court has decided to deny the “motion to d...
Storaffär i diabetesfältet I denna analysuppdatering lyfter vi fram en affär som nyligen gjorts i di...
Ett ”nytt” bolag i lansering- och kommersialiseringsfas… Vi initierar på Kebni som har flera stora p...
Förvärv indikerar riktningen framåt VO2 har meddelat förväven av Locads och Madington.
Redeye comment on Remedy’s Q1 business review. Sometimes milestone payments do not adapt to the quar...
Redeye comments on Alelion's Q1 report, where the gross margin was nine percentage points better tha...
Recyctec publicerade den 25 april år 2023 bolagets delårsrapport för det första kvartalet.
Scanfil reported 1% above our net sales forecast in Q1.
Redeye will likely keep its Base Case and forecasts largely unchanged following a solid Q1 report wi...
Scanfil’s Q1 was expected to be strong, however the results still clearly topped estimates by many p...
Prospekteringsbolaget Bluelake Minerals dotterbolag Vilhelmina Mineral har beviljats Natura 2000-til...
